Artelo Biosciences
ARTL
18 hedge funds and large institutions have $659K invested in Artelo Biosciences in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 6 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
0% less ownership
Funds ownership: 0.02% → 0.01% (-0%)
5% less funds holding
Funds holding: 19 → 18 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
33% less capital invested
Capital invested by funds: $984K → $659K (-$325K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCA
Snowden Capital Advisors
New York
|
+$46.7K |
| 2 |
Renaissance Technologies
New York
|
+$31.4K |
| 3 |
HF
HRT Financial
New York
|
+$11.9K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$7.81K |
| 5 |
KWP
Keystone Wealth Partners
Chandler,
Arizona
|
+$6.43K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KC
Kepos Capital
New York
|
-$104K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$88.1K |
| 3 |
VF
Virtu Financial
New York
|
-$66.6K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$41K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$14K |
ARTL Hedge Fund Activity: Q1 2022 in Review
18 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q1 2022, worth a combined $659K — down 33% from $984K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ARTL and 5 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 5 added.
The largest buyer was Snowden Capital Advisors, opening a new position worth an estimated $46.7K. The largest seller was Kepos Capital, exiting entirely with an estimated $104K sold.
- 18 institutional investors held Artelo Biosciences (ARTL) as of Q1 2022, down from 19 in Q4 2021.
- Funds reported $659K of Artelo Biosciences stock for Q1 2022, down 33% quarter-over-quarter.
- 5 funds opened new Artelo Biosciences positions in Q1 2022 and 6 closed out, a net change of -1 holder.
- The largest Artelo Biosciences buyer in Q1 2022 was Snowden Capital Advisors, an estimated $46.7K added.
- The largest Artelo Biosciences seller in Q1 2022 was Kepos Capital, an estimated $104K sold.
Based on aggregated 13F filings for Q1 2022.